First Phase II Hurdle Jumped, Chelsea’s Methotrexate Challenger Ready To Be Wooed
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has about a year of cash, and hopes positive data from the small trial is enough to snag a partner.
You may also be interested in...
More Methotrexate Please: Chelsea May Have Found End-Run To Dodge Toxicity
Company hopes to get quick approval of its low blood pressure drug droxidopa to help finance development, commercial organization for CH-1504, its methotrexate alternative.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.